Your money or your life

Drug companies are applying for patents on genes and their functions with unprecedented speed. Some of these patents are so far-reaching that, if granted, they could prevent anyone else from touching those genes to create drugs that act on them or even to test the genes for mutations in a patient. W...

Full description

Saved in:
Bibliographic Details
Published inNew scientist (1971) Vol. 175; no. 2351; pp. 28 - 33
Main Author Westphal, Sylvia Pagan
Format Magazine Article
LanguageEnglish
Published England New Scientist 13.07.2002
Subjects
Bioethics
Biomedical Research - economics
Breast cancer
Breast Neoplasms - genetics
Diagnostic Techniques and Procedures - economics
Drug Industry - economics
Europe
Female
Gene technology
Genes
Genes, BRCA1
Genes, BRCA2
Genetic Research - economics
Genetic Research - legislation & jurisprudence
Genetic Testing - economics
Humans
Industry - economics
Myriad Genetics
Ovarian Neoplasms - genetics
Patents as Topic - legislation & jurisprudence
Pharmaceutical industry
Pharmaceutical Preparations
Testing
United States
United States
Europe
Myriad Genetics Inc
Health Care and Public Health
Legal Approach
Biomedical and Behavioral Research
Online AccessGet full text

Cover

More Information
Summary:Drug companies are applying for patents on genes and their functions with unprecedented speed. Some of these patents are so far-reaching that, if granted, they could prevent anyone else from touching those genes to create drugs that act on them or even to test the genes for mutations in a patient. Westphal investigates this worrying trend.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
content type line 24
SourceType-Magazines-1
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0262-4079
2059-5387